https://scholars.lib.ntu.edu.tw/handle/123456789/638445
標題: | Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study | 作者: | Oh, Do-Youn Algazi, Alain Capdevila, Jaume Longo, Federico Miller, Wilson Chun Bing, Jerry Tan Bonilla, Carlos Eduardo Chung, Hyun Cheol Guren, Tormod K CHIA-CHI LIN Motola-Kuba, Daniel Shah, Manisha Hadoux, Julien Yao, Lili Jin, Fan Norwood, Kevin Lebellec, Loïc |
關鍵字: | immunotherapy; pembrolizumab; programmed cell death 1 ligand 1; programmed cell death 1 receptor; thyroid neoplasms | 公開日期: | 15-四月-2023 | 卷: | 129 | 期: | 8 | 來源出版物: | Cancer | 摘要: | The authors report results from the thyroid carcinoma cohort of the multicohort phase 2 KEYNOTE-158 study (NCT02628067), which evaluated pembrolizumab monotherapy in patients with previously treated cancers. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638445 | ISSN: | 0008543X | DOI: | 10.1002/cncr.34657 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。